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ABSTRACT
Background: Advanced glycation end products (AGEs) accumulate
in tissues with age and in conditions such as diabetes mellitus
and chronic kidney disease (CKD), and they may be involved in
age-related diseases. Skin AGEs measured as skin autofluorescence
(SAF) are a noninvasive reflection of long-term AGE accumulation
in tissues. Whether AGEs present in the diet (dAGEs) contribute to
tissue AGEs is unclear.
Objectives: Our aim was to investigate the association between
dietary and skin AGEs in the Rotterdam Study, a population-based
cohort of mainly European ancestry.
Methods: In 2515 participants, intake of 3 dAGEs [carboxymethyl-
lysine (CML), N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine
(MGH1), and carboxyethyl-lysine (CEL)] was estimated using
FFQs and the content of AGEs measured in commonly consumed
foods. SAF was measured 5 y (median value) later using an AGE
Reader. The association of dAGEs with SAF was analyzed in linear
regression models and stratified for diabetes and chronic kidney
disease (CKD, defined as estimated glomerular filtration rate ≤60
mL/min) status.
Results: Mean ± SD intake was 3.40 ±0.89 mg/d for CML, 28.98
±7.87 mg/d forMGH1, and 3.11±0.89 mg/d for CEL. None of them
was associated with SAF in the total study population. However, in
stratified analyses, CML was positively associated with SAF after
excluding both individuals with diabetes and individuals with CKD:
1 SD higher daily CML intake was associated with a 0.03 (95% CI:
0.009, 0.05) arbitrary units higher SAF. MGH1 and CEL intake were
not significantly associated with SAF. Nevertheless, the associations
were stronger when the time difference between dAGEs and SAF
measurements was shorter.
Conclusions:Higher dietary CML intake was associated with higher
SAF only among participants with neither diabetes nor CKD, which
may be explained by high AGE formation in diabetes and decreased
excretion in CKD or by dietary modifications in these disease
groups. The dAGE–SAF associations were also modified by the
time difference between measurements. Our results suggest that
dAGEs can influence tissue AGE accumulation and possibly thereby
age-related diseases. This trial was registered at the Netherlands
National Trial Register as NTR6831 (http://www.trialregister.nl/tri
alreg/admin/rctview.asp?TC=6831) and at the WHO International
Clinical Trials Registry Platform as NTR6831 (http://www.who.in
t/ictrp/network/primary/en/). Am J Clin Nutr 2020;00:1–9.




Advanced glycation end products (AGEs) are a cluster of
heterogeneous molecules that are formed endogenously through
nonenzymatic glycation of proteins, lipids, or nucleic acids
and subsequent chemical rearrangements (1). They accumulate
widely as part of normal aging, especially in long-lived tissues,
because of irreversible formation and limited clearance mostly
depending on tissue turnover rates (2). Independent of chronolog-
ical age, AGEs are involved in the pathophysiology of aging and
age-related disorders such as diabetes, cardiovascular diseases,
and dementia by forming cross-links, modifying structures of
proteins, or triggering inflammatory pathways by binding to
the AGEs receptor (3). The amount of AGEs in the skin has
been used as a reflection of the long-term accumulation of
AGEs because skin collagen on which the AGEs form has a
long half-life of ∼15 y (2, 4). Skin AGE measured as skin
autofluorescence (SAF) was recently found to be related to inci-
dent diabetes, cardiovascular events, and mortality among Dutch
people (5).
In addition to endogenous formation, AGEs are largely
ingested via diet (6). Both unprocessed and processed foods (e.g.,
sausage roll, beefsteak, and skimmed milk) can contain AGEs,
which are similar chemical entities as AGEs in vivo. Certain
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cooking conditions, such as high temperatures and low moisture
during frying, baking, and grilling, can produce more AGEs due
to excessive Maillard reactions taking place (7).
Several human, animal, and in vitro studies have suggested
the involvement of dietary AGEs (dAGEs) in, for example,
metabolic diseases (8, 9), cardiovascular diseases (9, 10),
diabetes (11), Alzheimer’s disease (12), food allergy (13),
and hampered skeletal muscle growth and muscle contractile
function (14). They can also trigger pathways related to cancer
risk (15). A large longitudinal population study showed that
dietary intake of carboxymethyl-lysine (CML)—one of the most
widely studied AGEs—was associated with modestly increased
risk of pancreatic cancer in men (but not in women, with a
smaller sample size) and might partially explain the positive
association between red meat intake and pancreatic cancer (16).
However, results on health outcomes are inconclusive because
several studies did not observe a protective effect from a low-
AGEs diet, whereas others observed a protective effect on, for
example, inflammation and cardiovascular risk (17, 18, 19).
The inconsistency in results might be explained by differences
in study design, population, or study duration ranging from a
few weeks to years (a short duration may not capture effects
adequately) (20).
Dietary AGEs may affect health via an effect on tissue AGE
accumulation (21). Although a link between dietary and serum
AGEs has been reported by several studies with small sample
sizes (22, 23) and previous studies estimated that 10–30% of
AGEs are absorbed into the circulation after oral administration
(24), whether excessive dAGE intake associates with more tissue
accumulation is unknown from large human studies. Deciphering
whether dAGEs influence tissue AGEs in an adequately sized
population is important to untangle the link between dAGEs and
disease risk.
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FIGURE 1 Participants inclusion and exclusion flowchart. dAGEs,
dietary advanced glycation end products; SAF, skin autofluorescence.
To narrow the gap, we studied associations between daily
intake of 3 dAGEs and skin AGEs in a population-based cohort—
the Rotterdam Study. The primary outcomewas the association of
dAGEs with SAF in the total study population, and the secondary
outcome was the association among participants without diabetes
or chronic kidney disease (CKD).
Methods
Study population
Study participants were from the Rotterdam Study (RS), which
was initiated in 1990when all inhabitants of the suburbOmmoord
in the city of Rotterdam aged ≥55 y were invited to participate.
The first subcohort (RS-I) included 7983 participants aged
≥55 y and started in 1990. The second subcohort (RS-II) included
3011 new participants aged ≥55 y and started in 2000. The third
subcohort (RS-III) included 3932 new participants aged ≥45 y
and started in 2006. All participants were examined at baseline,
and every 4–6 y follow-up examinations took place. The majority
of the study population is of European ancestry. The design and
objectives of the RS have been extensively described previously
(25). The RS was approved by the institutional review board
(Medical Ethics Committee) of Erasmus Medical Center and by
the review board of The Netherlands Ministry of Health, Welfare
and Sports. All participants in the current analysis provided
written informed consent to participate.
RS-I 5th, RS-II 3rd, and RS-III 1st visits constitute the baseline
of our study. Dietary data were available for 5508 participants
after excluding participants with implausible reported energy
intake values (<500 or >5000 kcal/d). For 2523 of the 5508
participants, skin AGEs were measured as SAF on average 5 y
later (RS-I 6th visit, RS-II 4th visit, and RS-III 2nd visit),
from which we excluded 8 outliers (> ±6 SD), leaving 2515
participants included. The flowchart for participant inclusion and
exclusion is shown in Figure 1.
Estimation of dietary AGE intake and other dietary
characteristics using FFQ
Participants received a semiquantitative 389-item FFQ when
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FIGURE 2 Overview of the procedure of linking of RS FFQ food items to AGEs database. AGE(s), advanced glycation end product(s); NL, The
Netherlands; RS, Rotterdam Study.
information covering the past month on food types, frequencies,
portion sizes, and some preparation methods. The FFQ has been
validated to properly rank subjects for nutrient intake among
Dutch adults (27, 28).
Referent AGE amounts in food items were derived from 2
published data sets: 1 primary Dutch database reporting CML,N-
(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MGH1), and
carboxyethyl-lysine (CEL) contents of 190 food items from
the contemporary Dutch population (29) and 1 complementary
database from Northern Ireland containing CML contents of 257
of the most commonly consumed foods by the Northern Irish
young adult population (30). For both databases, protein fractions
of food items were extracted and subsequently hydrolyzed
and then quantified by ultra-HPLC–tandem mass spectrometry
(UPLC-MS/MS). Although information on food processing
methods was lacking, it was assumed they were usual methods
that the RS population also followed, but differences in cooking
time and temperature cannot be taken into account.
Dietary intakes of 3 AGEs (CML, MGH1, and CEL) were
estimated following 4 steps. First, FFQ food items were matched
with items in the Dutch database. Second, food items not found
in the Dutch database were matched with items in the Northern
Ireland database. When multiple AGE values were provided in
the reference database for a single food item, the mean of all
the values was aligned. For example, for rye bread, the mean of
“rye bread, dark, brand A,” “rye bread, dark, brand B,” and “rye
bread, light” was used for the food item rye bread. For foods that
only presented as groups in the FFQ, the available food item that
represents the group or mean of the food items in the reference
databases was used. For example, the mean of “small cookies
and biscuits” and “spiced biscuit” was used to represent the food
small biscuits. Third, for single food items from the FFQ that
were not available in either of the databases, similar food items
were used. As a check, macronutrient composition was compared
between the missing food item and the replacement food item
through the Dutch Food Composition Database (NEVO) online
version 2016/5.0. For instance, the mean of available CML AGE
values for fruit and vegetables was assigned to other FFQ fruit
and vegetable food items. Last, for combination food items,
individual food components of the dish were computed according
to the contribution of ingredients in the dish based on information
on the package or standard recipe online. A detailed workflow is
shown in Figure 2.
The AGE intake of individual food items per day was
calculated by multiplying the AGE reference content in the food
item (mg/100 g) with the mean portion of the food item per day
(g/day; portion of the food item × frequency) (31). The daily
intake of 1 dAGE is the sum of its content in all food items. The
calculation was done for CML, MGH1, and CEL, respectively.
Dietary energy and macronutrients intake were calculated
using the NEVO. Overall diet quality was approximated in a
diet quality score (range: 0–14) reflecting adherence to the Dutch
dietary guidelines (26).
Measurement of SAF
During the visit to the RS research center, SAF of participants’
inner dominant forearm skin was measured using the AGE
Reader device (DiagnOptics), and the value was expressed in
arbitrary units (AU). Details of the measurement have been
described previously (32). The device utilizes the fluorescent
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against AGEs (pentosidine, CML, and CEL) measured in skin
biopsies from the same site at which SAF was measured (4).
Participants were asked not to use skin cream before the mea-
surement. We measured each participant 3 times consecutively,
and the mean was used for analyses. Extreme values in triple
measurements were pre-excluded as detected by the Grubbs test
and if the value exceeded the mean± 4 SD scope. The device also
measured skin UV reflectance reflecting the color of the skin. It
automatically excluded participants with darker skin with a mean
reflectance<6% and applied a correction on the SAF value if the
reflectance was between 6% and 10%.
Assessment of covariates at baseline
Other lifestyle, clinical, and dietary characteristics were
assessed at the time of FFQ collection. Physical activity,
smoking, alcohol intake, education level, medication use, and
medical history were measured during home interview and
were categorized later. Weight and height were measured
at the research center without shoes and with light clothes.
Blood samples were collected, and total cholesterol, HDL
cholesterol, triglycerides, creatinine, serum glucose, and insulin
were measured by standard techniques. European ancestry was
determined by genetic information. Briefly, the method utilized
the genetic data of the participants obtained from the single
nucleotide polymorphism array and the data of HapMap samples.
The genotype data were pruned to end up with a variant in linkage
equilibrium. The ADMIXTURE program was used to estimate
ancestry. Finally, ancestral groups were created based on having
≥50% genetic material from that ancestral group.
Physical activity was assessed using the LASA Physical Activ-
ity Questionnaire, and it expressed inmetabolic equivalents hours
per week (33), covering activities of walking, cycling, sports,
gardening, and housework. Smoking status was categorized as
never, past, or current smoker based on habits of cigarette,
cigar, and pipe smoking. Alcohol intake was harmonized to
grams of alcohol per day. Acquired highest level of education
was harmonized across all 3 RS subcohorts according to the
United Nations Educational, Scientific and Cultural Organization
classification (34).
BMI (in kg/m2) was calculated as weight divided by height2.
LDL cholesterol (millimoles per liter) was calculated using
the Friedewald formula. The estimated glomerular filtration
rate (eGFR; milliliters per minute per 1.73 m2) was calculated
using the Chronic Kidney Disease Epidemiology Collaboration
equation. CKD was defined as eGFR ≤60 mL/min per 1.73 m2.
Diabetes was defined as fasting serum glucose concentration
≥7.0 mmol/L or the use of antidiabetic medication or self-
reported as having diabetes during home interviews.
Statistical analysis
Statistical analyses were performed using SPSS 24 software
(IBM). Descriptive statistics described the lifestyle, clinical, and
dietary characteristics of the study population. Normality was
determined based on histograms and quantile–quantile plots.
Depending on the normal or nonnormal distribution, data were
represented as respectively means ± SDs or medians (IQR). We
divided the population into 3 equal frequency groups with low,
medium, and high CML intake (adjusted for age and sex) to show
the inequality in the mean or median values of covariates. Briefly,
we calculated the residuals for every individual from the linear
regression model in which CML was the dependent variable and
age and sex were the independent variables. Participants were
categorized into 3 groups by tertiles of residuals.
We used energy-adjusted intake of CML, MGH1, and CEL for
analyses to reduce bias caused by self-reported FFQ information.
They were calculated by the residual method, namely by adding
the mean dAGE intake and the residuals of dAGE intake
adjusted by energy intake in the linear regression (35). All dAGE
intakes we referred to were energy-adjusted dAGE intakes unless
specified. Contributions of individual food categories to AGE
intake were the category-specific AGE amount divided by the
total AGE intake.
The intake of CML, MGH1, and CEL was rescaled to
z scores with mean = 0 and SD ± 1, respectively. Subsequently,
multivariable linear regression models were constructed with
SAF as the outcome and z scores of dAGE intake as exposures.
Results of CML intake are discussed in the Results section, and
the results of the other 2 dietary AGEs are presented in the
supplemental materials. Potential confounders were identified
based on a combination of literature review and biological
reasoning, such as increased AGE accumulation under diabetic
or CKD conditions (32). Then we restricted covariates to the
ones that are (proxy of) shared causes (risk factors) of dAGEs
and SAF to remove redundancy and overfitting problems in the
models (36).We built 3 confoundermodels: model 1was adjusted
for age, sex, and RS subcohorts; model 2 was additionally
adjusted for energy intake and physical activity; and model 3
was further adjusted for diet quality, smoking status, eGFR, and
diabetes status.
Multicollinearity was assessed by tolerance tests, with a
tolerance level of 0.40 considered threshold. Heteroscedasticity
was determined by plotting the linear regression residuals
against the predicted outcome value. P < 0.05 was regarded as
statistically significant.
Participants with different age or sex may show differences
in physiology and dietary pattern. Diabetes mellitus and CKD
are well-established risk factors for excessive tissue AGE
accumulation and higher SAF; on the other hand, people may
receive dietary recommendations because of the diseases that
may influence AGE accumulation. Thus, the potential effect
modification of the association between dAGEs and SAF by age,
sex, diabetes status, CKD status, and diet quality was checked
by adding 2-way interaction terms between suspected effect
modifiers and dAGEs into linear regression model 3. In the
case of significant interaction (P < 0.1), stratified analyses were
performed. Unless specified, the results shown in this article were
obtained from model 3.
We observed a range from 0.4% to 5.8% of missing data
for physical activity (n = 146, 5.8%), smoking status (n = 9,
0.4%), eGFR (n= 47, 1.9%), diabetes status (27, 1.1%), and BMI
(n= 14, 0.6%). They were imputed by multiple imputation under
the missing at random assumption using the predictive mean
matching method (37). Ten imputation results were acquired
through 10 iterations per imputation. The results from the 5th
imputation were used to replace the missing value in covariates.
We performed the analyses in both the population after missing
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TABLE 1 Characteristics of the study population by tertiles of dietary CML intake (age and sex adjusted)1
Total Low CML Medium CML High CML
Characteristic (n = 2515) (n = 838) (n = 838) (n = 839)
CML, mg/d (energy-adjusted) 3.40 ± 0.89 2.55 ± 0.48 3.30 ± 0.19 4.33 ± 0.72
Age, y 67.76 ± 9.59 66.90 ± 9.46 68.62 ± 9.03 67.75 ± 10.17
Sex (women) 1432 (57) 474 (57) 481 (57) 477 (57)
Time between FFQ and SAF measurement 5.00 (4.54, 5.57) 5.13 (4.55, 5.58) 4.82 (4.53, 5.54) 5.12 (4.56, 5.57)
Education level (n = 2476)
Primary, n (%) 157 (6) 54 (7) 52 (6) 51 (6)
Lower, n (%) 963 (39) 319 (39) 338 (41) 306 (37)
Intermediate, n (%) 760 (31) 254 (31) 253 (31) 253 (31)
Higher, n (%) 596 (24) 201 (24) 180 (22) 215 (26)
Physical activity, MET h/wk (n = 2369) 42.50 (17.55, 83.86) 42.07 (17.00, 86.13) 44.54 (17.86, 84.22) 41.50 (17.93, 81.15)
Alcohol intake, g/d (n = 2289) 8.57 (1.61, 8.57) 8.57 (6.43, 15.00) 8.57 (1.61, 8.57) 6.43 (1.52, 8.57)
Smoking status (n = 2506)
Never, n (%) 800 (32) 227 (27) 280 (34) 293 (35)
Former, n (%) 1347 (54) 463 (55) 437 (53) 447 (53)
Current, n (%) 359 (14) 147 (18) 115 (14) 97 (12)
Coffee intake,2 g/d 406 (174, 406) 406 (174, 406) 406 (174, 406) 406 (174, 406)
BMI, kg/m2 (n = 2501) 27.47 ± 4.25 27.21 ± 4.16 27.62 ± 4.24 27.59 ± 4.35
Fasting serum glucose, mmol/L (n = 2472) 5.40 (5.10, 5.90) 5.40 (5.10, 5.90) 5.50 (5.10, 6.00) 5.40 (5.10, 5.90)
Total cholesterol, mmol/L (n = 2472) 5.46 ± 1.07 5.52 ± 1.08 5.47 ± 1.06 5.39 ± 1.06
HDL cholesterol, mmol/L (n = 2472) 1.42 (1.19, 1.71) 1.42 (1.22, 1.73) 1.46 (1.21, 1.74) 1.39 (1.14, 1.67)
Triglycerides, mmol/L (n = 2472) 1.26 (0.96, 1.73) 1.28 (0.94, 1.75) 1.24 (0.97, 1.68) 1.26 (0.96, 1.75)
eGFR, mL/min per 1.73 m2 (n = 2468) 78.70 (68.12, 88.01) 80.15 (69.71, 89.00) 77.35 (67.64, 86.83) 78.64 (67.17, 87.60)
Chronic kidney disease (n = 2468) 296 (12.0) 92 (11.2) 97 (11.8) 107 (13.0)
Diabetes (n = 2488) 303 (12.2) 82 (9.9) 114 (13.8) 107 (12.9)
Energy intake, kcal/d 2140 ± 681 2212 ± 714 1984 ± 645 2224 ± 655
Protein intake, g/d 82.0 ± 25.4 78.8 ± 24.8 78.0 ± 23.8 89.4 ± 26.1
Carbohydrate intake, g/d 240.7 ± 85.0 246.3 ± 91.2 224.0 ± 80.7 251.7 ± 80.0
Fat intake, g/d 71.3 (54.9, 92.5) 70.7 (54.3, 93.9) 68.0 (51.2, 86.1) 75.5 (58.9, 97.6)
Diet quality score 7.0 ± 1.9 6.6 ± 1.9 7.0 ± 1.8 7.3 ± 1.8
MGH1, mg/d (energy-adjusted) 28.98 ± 7.87 24.36 ± 5.86 28.95 ± 5.10 33.62 ± 9.10
CEL, mg/d (energy-adjusted) 3.11 ± 0.89 2.55 ± 0.64 3.11 ± 0.60 3.66 ± 0.99
SAF, AU 2.40 ± 0.50 2.38 ± 0.50 2.43 ± 0.50 2.40 ± 0.51
1Values are n (%) or means ± SDs if normally distributed and medians (IQRs) if nonnormally distributed, n = 2515 unless otherwise indicated. The low,
medium, and high CML intake groups were determined by tertiles of energy-adjusted CML intake after adjusting for age and sex in linear regression.
Energy-adjusted AGEs were calculated by adding the mean dAGEs intake and residuals of dAGEs adjusted by energy intake in the linear regression. AGEs,
advanced glycation end products; AU, arbitrary units; CEL, carboxyethyl-lysine; CML, carboxymethyl-lysine; dAGEs, advanced glycation end products
present in the diet; eGFR, estimated glomerular filtration rate; MET, metabolic equivalent of task, with 1 MET defined as 1 kcal/kg/h; MGH1,
N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine; SAF, skin autofluorescence.
2Identical values in coffee intake by coincidence.
In addition, several sensitivity analyses were performed (1).
Because BMI and dietary macronutrients could be potential
confounders as well as covariates on the pathway of the dAGEs–
SAF link, as a sensitivity test, we further adjusted for BMI
and macronutrient intake in addition to model 3 and the results
were compared (2). All analyses were repeated in participants
of European ancestry (3). A longer time interval between
assessment of dAGEs and skin AGEs may in theory dilute
the dAGEs–SAF association because of changes in dietary
habits, health status, or metabolism. Therefore, we further
explored the effect of time difference between dAGEs and SAF
measurements on the dAGEs–SAF association by including
an interaction term of time difference with dAGEs to linear
regression model 3. Furthermore, we generated plots to show
the change of association along incremental time difference
between measurements (“interplot” package in R, version 3.6.1;
R Foundation for Statistical Computing).
Results
Descriptives
In total, 2515 participants (aged 67.8 ± 9.6 y, 56.9% female)
were included in the study. For CML intake calculation, 246
items of the FFQ had values matched from the Dutch database
and 121 items had values matched from the Northern Ireland
database. After energy adjustment, mean dietary intake per day
was 3.40 ± 0.89 mg for CML, 28.98 ± 7.87 mg for MGH1, and
3.11 ± 0.89 mg for CEL (Table 1). The top 5 food categories
(by mean values) contributing to the CML intake were milk,
whole grain, unprocessed meat, refined grains, and pulses.
Details on the contribution of food categories to 3 types of AGE
intake are shown in Supplemental Table 1 and Supplemental
Figure 1.
In the total study population, mean SAF value was 2.40± 0.50
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TABLE 2 The association between CML intake and SAF in the total study population and in subgroups based on disease status1
Coefficient (95% CI)
Group n Model 1 Model 2 Model 3 P-interaction
Total 2515 0.009 [−0.01, 0.027] 0.008 [−0.011, 0.026] 0.011 [−0.007, 0.029]
Nondiabetes 2185 0.012 [−0.007, 0.032] 0.012 [−0.008, 0.031] 0.019 [−0.001, 0.038] 0.062
Diabetes 303 − 0.036 [−0.093, 0.02] − 0.037 [−0.094, 0.019] − 0.036 [−0.092, 0.021]
Non-CKD 2172 0.015 [−0.005, 0.034] 0.014 [−0.005, 0.034] 0.018 [−0.001, 0.038] 0.033
CKD 296 − 0.044 [−0.105, 0.017] − 0.044 [−0.105, 0.017] − 0.04 [−0.101, 0.021]
With neither diabetes nor CKD 1914 0.021 [0.001, 0.042] 0.021 [0, 0.042] 0.03 [0.009, 0.05]
1Among the 2515 participants, 553 individuals had either diabetes or CKD or both diseases (n = 303 diabetes, n = 296 CKD), 1914 individuals did not
have either diabetes or CKD, and for 48 individuals the diabetes and CKD status could not be determined due to missing information. Regression coefficients
[95% CIs] of CML z score were estimated from the linear regression models and represent the adjusted difference of SAF (AU) associated with one SD
difference of dietary CML intake. Model 1 adjusted for age, sex, and RS subcohorts; model 2 further adjusted for energy intake and physical activity; model 3
adjusted for diet quality score, smoking status, eGFR, and diabetes status (except for subgroups categorized by diabetes status) in addition to model 2. AU,
arbitrary units; CKD, chronic kidney disease; CML, carboxymethyl-lysine; eGFR, estimated glomerular filtration rate; RS, Rotterdam Study; SAF, skin
autofluorescence.
2Model: SAF ∼ CML + age + sex + RS subcohorts + energy intake + physical activity + diet quality score + smoking status + eGFR + diabetes
status + CML × diabetes status.
3Model: SAF ∼ CML + age + sex + RS subcohorts + energy intake + physical activity + diet quality score + smoking status + CKD
status + diabetes status + CML × CKD status.
12.2%) or CKD (296, 12.0%) at baseline, 1914 individuals had
neither diabetes nor CKD, and 48 individuals had undetermined
diabetes and CKD status because of missing information. In
low, medium, and high CML tertiles, energy-adjusted CML
intake was 2.55 ± 0.48, 3.30 ± 0.19, and 4.33 ± 0.72 mg/d,
respectively. The low CML intake group had the lowest SAF,
and the medium CML intake group had the highest SAF.
Compared with the low and high CML tertiles, the medium
CML tertile was characterized by older age; lower eGFR; lower
total energy intake; lower carbohydrate, fat, and protein intake;
higher serumHDL cholesterol; and higher prevalence of diabetes.
Across CML tertiles, higher CML intake was accompanied by
a higher prevalence of CKD, a lower percentage of current
smokers, and a higher adherence to the Dutch Dietary Guidelines
(Table 1).
The association between dietary AGE intake and SAF
In multiple linear regression analyses, we did not observe any
association between CML and SAF after adjustment for age,
sex, and RS subcohorts (adjusted mean difference per SD higher
CML = 0.009; 95% CI: −0.01, 0.027) or further adjustment for
energy intake, physical activity, dietary quality, smoking status,
diabetes status, and eGFR (adjusted mean difference per SD
higher CML = 0.011; 95% CI: −0.007, 0.029) (Table 2). The
linearity of the linear regression models is met as the residuals
against the fitted value of the linear regression model were
symmetrically distributed with constant variance, and adding a
squared term of CML intake did not improve the model fit.
We did not observe significant effect modification by
age, sex, and dietary quality score on the dAGEs–SAF
association. Potential effect modification for the association
was observed for diabetes status (P value for interaction:
Pdiabetes status × CML = 0.06) and for CKD status (P value for
interaction: PCKD status × CML = 0.03 if the main effect of eGFR
in model 3 was replaced by CKD). A detailed comparison of
demographic, lifestyle, and clinical characteristics of participants
by diabetes and CKD status is shown in Supplemental Table 2.
The energy-adjusted CML intake was 3.42 ± 0.86 mg/d
for diabetics, 3.35 ± 0.90 mg/d for CKD participants, and
3.39 ± 0.88 mg/d for participants with neither diabetes nor
CKD. The age of these groups was 70.9 ± 7.8, 75.1 ± 6.9, and
66.4 ± 9.5 y, respectively.
Stratified analysis of model 3 by diabetes and CKD showed
that higher dietary CML intake was not significantly associated
with higher SAF in the nondiabetes group nor in the non-
CKD group. Because renal insufficiency is one of the major
diabetes complications, we checked for overlap between CKD
and diabetes, which was not very large (16.6% of the diabetic
participants had CKD compared with 11.4% of nondiabetics).
The positive association between CML intake and SAF was
present after excluding both individuals with diabetes and
individuals with CKD (adjusted mean difference per SD higher
CML = 0.03; 95% CI: 0.009, 0.05). The results of stratified
analyses are shown in Table 2. Due to the age differences
in the subgroups of participants by diabetes and CKD status,
we examined the dAGEs–SAF association among different
age groups. Stratifying the total population by age ≥70 y
(the median age) or age <70 y did not exhibit substantial
difference in effect size in results of model 3 [0.017 (95%
CI: −0.013, 0.046) compared with 0.009 (95% CI: −0.014,
0.032)].
All 3 dietary AGEs were correlated [Pearson correlation
coefficient (r) between MGH1 and CEL was 0.810, that between
CEL and CML was 0.582, and that between MGH1 and CML
was 0.545; P < 0.0001 for all]. The associations between other
types of AGEs and SAF were less strong than that of CML
because none of them was significant in the total population
and in stratified analysis, although the coefficients were similar
(Supplemental Table 3, Supplemental Figure 2).
Using the unimputed complete record data set exhibited
similar results (Supplemental Table 4). Additional adjustments
in model 3 for BMI and dietary protein and fat intake did not
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repeated the analysis of the association between CML intake and
SAF in participants of European ancestry and the results were
similar (Supplemental Table 6).
Furthermore, time difference between dAGEs and SAF
measurements modified the dAGEs–SAF association, indicated
by the interaction terms included additionally in model 3 in
2515 participants (P value for interaction: PCML × time = 0.06,
PMGH1 × time = 0.15, and PCEL × time = 0.06). Because we ob-
served the association among participants with neither diabetes
nor CKD, Supplemental Figure 3 shows how coefficients of
dAGEs changed along the time difference betweenmeasurements
in this subpopulation. We observed a stronger positive associ-
ation between dAGEs and SAF for a shorter time difference,
and the point estimate of coefficient decreased as the time
difference increased, although the 95% CI overlapped. For
longer time differences, the point estimates of the coefficient
became negative; however, there were sparse participants
with a very large time difference between dAGEs and SAF
measurements.
Discussion
Interested in the association between dietary and tissue AGEs,
we calculated the dietary AGEs from the FFQ and assessed
skin AGEs as SAF in a large population-based cohort. The
distributions of dAGEs are comparable to those of another study
using the same reference database (38). No association was
observed in the total population, but higher CML–AGE intake
was weakly but significantly associated with higher SAF among
participants with neither diabetes nor CKD.
One can assume that dietary AGEs will go through a complex
cascade of transportations and metabolism from ingestion to skin
deposition and are influenced by complex dietary, metabolic, and
physiological conditions. However, after adjusting for several
influencing factors, 1 SD (0.89 mg) difference in daily CML
intake was still associated with 0.030 (95% CI: 0.009, 0.050)
AU difference in SAF in people with neither diabetes nor
CKD, which is considerable compared with an approximate
0.024 AU natural yearly increase reported for healthy people
<70 y (39). Diabetes and CKD are well-known risk factors
for AGE accumulation due to hyperglycemia that results in
high formation or reduced AGE elimination through kidney (3,
40). For participants with diabetes or CKD, a small increase
in skin AGEs due to dietary AGEs may go undetected because
of the predisposed large amount of AGEs in the skin. We also
cannot rule out the possibility of dietary alterations because of
the diseases. Nonetheless, the association among diabetic and
CKD participants remains inconclusive due to inadequate sample
size.
The dAGEs–SAF association was further strengthened by
the results showing the time difference between dAGEs and
SAF measurements did modify the associations of all 3 types
of dAGEs with SAF. One of the explanations for a stronger
association for smaller time differences between measurements
is that the larger time difference could lead to changes in diet,
health status, or metabolism. In addition, the association may
fade with time as more clearance of previously formed skin AGEs
occurs despite the continuing exposure of dAGEs. Future studies
may explore the range of time interval fits for best capturing the
association.
The other 2 dAGEs, MGH1 and CEL, were more correlated
with each other than with CML, which could be partly due to the
fact that CML has a richer reference source with additionally the
Northern Ireland database. The 3 dAGEs we studied constitute
only part of a variety of dAGEs, let alone the AGE precursors,
but their contents in the Dutch diet are not yet available (1, 41).
However, the high correlations among intakes of the 3 different
types of dAGEs implied their rankings are likely representative
of other dAGEs.
Direct evidence for deposition of dietary CML in multiple
tissues was observed in mice after 30 d of oral administration of
13C-labeled CML (42). However, only a few human studies are
available focusing on circulating or urinary AGEs (43) instead
of tissue AGEs. For example, in 172 healthy individuals, dietary
CML from 3-d food records was positively correlated with
circulating CML (23). Our results are in line with this in the sense
that high dAGEs increase the circulating load of AGEs, and thus a
long-term AGE-rich diet may contribute to a higher load of tissue
AGEs (23, 43). Results from the CODAM Study (n= 450) using
the same Dutch AGE reference database (38) further support
our observation: in that study, dAGEs were nonsignificantly
positively associated with their corresponding protein-bound
AGEs in plasma, with the exception of a positive association with
free AGEs in plasma and urine. Although circulating protein-
bound AGEs do not have as low a turnover as tissue AGEs, their
half-life is longer than that of free forms in the circulation, and
they may thus be more relevant to the cumulative AGE load.
Nonetheless, unlike our study, their population had a high risk of
cardiovascular disease, including a larger proportion of diabetes,
but had fewer participants with CKD. In 73 elderly Dutch people
with an increased risk of cardiovascular disease, dietary AGEwas
not related to SAF, but this study lacked statistical power and used
a foreign AGE reference database (44). Other dietary factors have
also been shown to contribute to AGE accumulation, including
the Mediterranean diet and coffee intake (45, 46). Adjusting
for dietary quality score as a proxy for dietary quality did not
modify the association in our analysis, nor did adjusting for
coffee.
The disposition and metabolic transition of dAGEs to en-
dogenous AGEs remain unclear. We estimated the protein-bound
AGEs in the diet, but AGEs can present both in free forms
and in protein- and lipid-bound forms. Protein-bound AGEs
can be digested into free AGE molecules or continue to bind
to peptides and protein fractions. Free CML can enter the
circulation by passive penetration (47, 48), whereas dipeptide-
bound CML is likely to be transported actively by the peptide
transporter 1 into intestinal epithelium cells and may enter the
circulation as AGE-modified amino acids after peptidolysis (49).
Notably, transportability can depend on the type of AGE (48,
50). In addition, dietary AGEs might provoke endogenous AGE
formation by, for example, increasing inflammation (51).
The strengths of our study include a well-phenotyped and
intensively followed population with adequate sample size.
We were able to control for confounding by adjusting for
the dietary quality of each individual using a validated index.
Moreover, we provided a reliable and representative estimation
of habitual intake of 3 AGEs by using a well-validated
FFQ covering most of the daily-consumed foods. A domestic
contemporary AGE database was chosen as our main reference
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FFQ. AGEs were quantified by UPLC-MS/MS technology in
this database, outperforming the immunological methods in
veracity and precision, and were expressed in easy-to-interpret
units of milligrams per 100 grams rather than international
units.
However, several limitations are also present. The results
are restricted to the elderly Dutch population, although the
diet shares similarities with those of other Western countries.
The results should be interpreted with caution because we
did not correct for multiple comparisons, which may give
rise to false-positive findings. However, the subgroups were
predefined based on disturbed regulation of AGEs in patients
with diabetes and CKD. The fact that we observed that the time
difference between dAGEs and SAF measurements modified
the associations, with the strongest effects in the group with
shorter time difference, suggests that the associations between
dAGEs and skin AGEs are real and possibly underestimated in
our study. Furthermore, detailed information on food processing
methods was lacking, and intake of some nonperfect matched
food items was replaced by mean values because the FFQ
contained more items. Therefore, the variation in dAGE data
is likely to be underrepresented, and this could have weakened
any association. Last, we cannot rule out residual confounding
mainly from complex dietary factors, recoding bias, and healthy
survival effects, nor can we demonstrate whether relations are
causal.
Future research is warranted on the influence of dAGEs on
tissue deposition and ultimately on health outcomes, preferably
in large cohorts with repeated measurements of SAF and dAGEs.
Unified quantification methodology will reduce heterogeneity
and facilitate comparison among studies. Domestic data sources
on more AGE-related entities will also be helpful.
In conclusion, we found that there is a weak positive relation
between dietary CML intake and AGE accumulation in the skin
in persons with neither diabetes nor CKD, but not in those with
diabetes or CKD. This observation suggests that dietary intake
of AGEs may increase the AGE burden in tissues. The findings
require replication in longitudinal studies or in randomized
controlled trials.
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